Skip to main content

Table 1 Patient characteristics and variables associated with PONV

From: Haloperidol dose combined with dexamethasone for PONV prophylaxis in high-risk patients undergoing gynecological laparoscopic surgery: a prospective, randomized, double-blind, dose-response and placebo-controlled study

 

Group H0 (n = 50)

Group H1 (n = 49)

Group H2 (n = 50)

Age (year)

40 (20–60)

39 (20–60)

41 (21–58)

Weight (kg)

56.9 (5.7)

55.0 (7.9)

54.4 (5.3)

Height (cm)

158.7 (4.9)

159.1 (5.5)

157.3 (5.5)

ASA I/II

40/10

41/8

39/11

PONV or motion sickness history

26 (52 %)

28 (57 %)

28 (56 %)

Anesthesia duration (min)

150.3 (43.1)

157.9 (39.4)

156.4 (31.4)

Remifentanil consumption (μg)

104.7 (36.2)

97.2 (31.3)

92.5 (29.2)

Surgical type

   

 Lap. ovarian cystectomy

17 (34 %)

12 (24 %)

13 (26 %)

 Lap. hysterectomy

23 (46 %)

22 (45 %)

26 (52 %)

 Diagnostic laparoscopy

5 (10 %)

11 (22 %)

6 (12 %)

 Lap. myomectomy

4 (8 %)

3 (6 %)

4 (8 %)

 Lap. adhesiolysis

1 (2 %)

1 (2 %)

1 (2 %)

PCA fentanyl consumption for 24 h (μg)

470.1 (105.5)

465.6 (102.6)

467.8 (99.5)

Postoperative pain

   

 0-2 h

4.9 (1.7)

4.8 (1.8)

4.6 (2.1)

 2-24 h

2.2 (2.1)

2.8 (1.6)

2.2 (1.9)

Rescue analgesic requirements

15 (30 %)

11 (22 %)

10 (20 %)

  1. Values are means (SD) or number (proportion). No statistically significant difference was observed among the groups
  2. Group H0 = saline, H1 = haloperidol 1 mg, and H2 = haloperidol 2 mg
  3. PONV postoperative nausea and vomiting; Lap laparoscopic; PCA patient-controlled analgesia